Highlights:
✅ How to Phenotype HF-CS
✅ Benefits of early PAC
✅ Nomenclature of HF-CS w/ SCAI-CSWG classification
✅ Endpoints to follow in response to therapy
✅ Inotrope choice, Hemodynamic Targets, choosing an MCS strategy
Hoping this can be a valuable primer for trainees, Intensivists, Adv HF and Gen Cardiologists